Abstract
Distant metastasis is the predominant site of gastric cancer recurrence and the most common cause of death. Recently, accumulating evidence has established that aberrant epithelial-mesenchymal transition activation plays a crucial role in the genesis, invasion, and metastasis of various cancers, including breast cancer. In this paper, we found that miR-137, which has been reported to function as a tumor suppressor in a variety of cancers, could significantly suppress the migration and invasion of MCF-7 cells, which might be correlated with its suppressive effects on the EMT procedure. Upon transfection, the epithelial marker, E-cadherin, was up-regulated, and the mesenchymal markers, N-cadherin and Vimentin, were suppressed. Moreover, we also found that carboxyl-terminal binding protein 1 (CtBP1) was a putative target gene of miR-137 in MCF-7 cells, and might be involved in the suppressive effects, which might provide novel diagnostic and therapeutic options for human breast cancer in the future.
References
Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S M Frisch
Aug 26, 1998·The American Journal of Pathology·S Hirohashi
Aug 19, 2000·Oncogene·M L Grooteclaes, S M Frisch
Mar 13, 2003·Breast Cancer Research : BCR·Anne Vincent-Salomon, Jean Paul Thiery
Jan 28, 2004·Cell·David P Bartel
Feb 24, 2006·Nature Reviews. Molecular Cell Biology·Jean Paul Thiery, Jonathan P Sleeman
Sep 5, 2006·Cancer Research·Jason J Christiansen, Ayyappan K Rajasekaran
Jan 19, 2007·Nature Reviews. Genetics·Kevin Chen, Nikolaus Rajewsky
Jan 22, 2009·Cancer Research·G Chinnadurai
Apr 4, 2009·The American Journal of Pathology·Michael W Klymkowsky, Pierre Savagner
Jun 3, 2009·The Journal of Clinical Investigation·Raghu Kalluri, Robert A Weinberg
Dec 1, 2009·Cell·Jean Paul ThieryM Angela Nieto
Mar 26, 2010·Proceedings of the National Academy of Sciences of the United States of America·Michael L GatzaJoseph R Nevins
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Ming LiuFeng Bi
Aug 5, 2010·Cancer Research·Francesc BalaguerAjay Goel
Nov 6, 2010·Investigative Ophthalmology & Visual Science·Xiaoyan ChenLili Tu
Feb 1, 2011·International Journal of Biological Sciences·Yu DengQinghong Zhang
Jun 2, 2012·The Lancet Oncology·Yi W KongMartin Bushell
Jun 23, 2012·PloS One·Yuanyin ZhaoFengtian He
Nov 28, 2012·Acta Biochimica Et Biophysica Sinica·Xiaolan ZhuWenlin Xu
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Carol DeSantisAhmedin Jemal
Oct 15, 2013·Scientific Reports·Qian LiangJun Lu
Oct 16, 2013·Endocrine Pathology·Celina Montemayor-GarciaRicardo V Lloyd
Nov 19, 2013·Human Cell·Yueyang BiXiaozhi Wang
Jan 8, 2015·Expert Opinion on Therapeutic Targets·Minal Garg
Citations
Dec 24, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yingwei LuoWeifeng Sun
Jan 13, 2017·Journal of Proteome Research·Yu-Dong CaiTao Huang
Jun 9, 2016·Reproductive Sciences·Tan-Min LuLong-Jun Zhao
Apr 21, 2019·RNA·Mitzli X VelascoLuiz O F Penalva
Jul 28, 2016·Oncotarget·Ying ZhuHua Tang
May 31, 2019·Cancer Cell International·Hui MiaoWen-Bo Song
Dec 11, 2019·International Journal of Molecular Sciences·Soo Jung LeeYee Soo Chae
Apr 2, 2019·Oncology Letters·Juan GuoXinghua Long
Jun 18, 2020·OncoTargets and Therapy·Niuniu LiTieyan Wang
Oct 12, 2021·Oncology Letters·Yuluo Wu, Haiyang Zhao
Jun 27, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jian ZhangLe Zhang